SAN DIEGO, Feb. 23, 2024 /PRNewswire/ -- PassPort Technologies, Inc. (PPTI), based in San Diego, initiated a US Phase 1 clinical study of Zolmitriptan PassPort® utilizing its proprietary transdermal microporation system, PassPort® platform technology. The study objectives are to evaluate the safety of PassPort® system and pharmacokinetics to anticipate a faster onset of action compared to zolmitriptan oral tablet.

圣地亚哥，2024年2月23日/PRNewswire/--总部位于圣地亚哥的PassPort Technologies，Inc.（PPTI）利用其专有的透皮微定量系统PassPort®平台技术，启动了佐米曲普坦PassPort®的美国1期临床研究。研究目标是评估PassPort®系统的安全性和药代动力学，以预期与佐米曲普坦口服片剂相比起效更快。

Zolmitriptan, marketed under the brand name ZOMIG®, is an FDA-approved prescription medication used for treating migraine symptoms. 'We believe our Zolmitriptan PassPort® provides significant advantages of faster onset of action and higher efficacy for migraine patients with severe nausea and patients who are non-responsive to oral triptans' said President and CEO Tomoyuki Fujisawa.An open-label, randomized, crossover study consisting of 32 healthy volunteers is testing the safety, tolerability, and pharmacokinetics of Zolmitriptan PassPort® with 3 different doses, administered to the subject's upper arm, compared to oral administration of zolmitriptan.

佐米曲普坦以ZOMIG®品牌销售，是FDA批准的用于治疗偏头痛症状的处方药总裁兼首席执行官藤泽友之（Tomoyuki Fujisawa）表示，我们相信佐米曲普坦护照®对于严重恶心的偏头痛患者和口服曲坦类药物无反应的患者具有起效更快、疗效更高的显著优势。一项由32名健康志愿者组成的开放标签随机交叉研究正在测试佐米曲普坦PassPort®的安全性，耐受性和药代动力学，与口服佐米曲普坦相比，给受试者上臂服用3种不同剂量。

Additionally, the study will evaluate the transdermal administration of a single dose at alternative sites, the subject's abdomen and upper thigh. Interim pharmacokinetic data will be available to the public in March 2024..

此外，该研究将评估在替代部位，受试者的腹部和大腿上部的单剂量透皮给药。中期药代动力学数据将于2024年3月向公众提供。。

Continue Reading

继续阅读

About PassPort Technologies, Inc. As a cutting-edge biotechnology entity, PPTI is committed to the swift development and patient delivery of exceptional pharmaceuticals through the PassPort® system. The company aims to constantly develop technologies that serve the pharmaceutical industry and broader life sciences sectors.

关于PassPort Technologies，Inc.作为一家尖端的生物技术实体，PPTI致力于通过PassPort®系统快速开发和向患者提供优质药物。该公司旨在不断开发为制药行业和更广泛的生命科学部门服务的技术。

PPTI's mission is to advance global health outcomes. Further details can be found at https://passport-tech.com..

PPTI的使命是促进全球健康成果。有关更多详细信息，请访问https://passport-tech.com..

PassPort® platform technology will be able to provide faster onset of action and higher efficacy benefiting severe migraine patients.

PassPort®平台技术将能够提供更快的起效时间和更高的疗效，从而使严重偏头痛患者受益。

Post this

发布此

About PassPort® Technology The PassPort® System integrates patented painless skin microporation and dry patch formulation technologies to regulate drug delivery through the micropores created in the skin. This innovative system enables transdermal delivery of not only small molecules but also peptides, proteins, and RNAs for therapeutics and infection vaccines..

关于PassPort®技术PassPort®系统集成了获得专利的无痛皮肤微孔和干贴剂配方技术，以通过皮肤中产生的微孔调节药物输送。这种创新系统不仅可以透皮递送小分子，还可以透皮递送用于治疗和感染疫苗的肽，蛋白质和RNA。。

Forward-Looking StatementExcept for historical information, all the statements, expectations, and assumptions contained in this Press Release are forward-looking statements. Actual results may differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the early phase of the clinical trial; risks associated with the drug development process; competition; reliance on key personnel; and other risks described in other PassPort Technologies, Inc.

前瞻性声明除历史信息外，本新闻稿中包含的所有声明、期望和假设均为前瞻性声明。实际结果可能与前瞻性声明中明确或隐含的结果存在重大差异。可能导致实际结果产生重大差异的重要因素包括：临床试验的早期阶段；与药物开发过程相关的风险；竞争；依赖关键人员；以及其他PassPort Technologies，Inc.中描述的其他风险。

press releases and presentations.SOURCE PassPort Technologies, Inc..

新闻稿和演示文稿。SOURCE PassPort Technologies，Inc。。